The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders Gustavo GramppSundar Ramanan Current Opinion Open access 18 November 2015 Pages: 365 - 372
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers Kevin KleinMarie L. De BruinPieter Stolk Short Communication Open access 30 November 2015 Pages: 373 - 379
A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects Donghoon ShinYoungdoe KimRainard Fuhr Original Research Article Open access 17 November 2015 Pages: 381 - 388
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden Jenny M. NorlinKatarina Steen CarlssonMarcus Schmitt-Egenolf Original Research Article 15 December 2015 Pages: 389 - 398
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease Katherine A. Lyseng-Williamson Adis Drug Evaluation 22 September 2015 Pages: 399 - 406
Dulaglutide: A Review in Type 2 Diabetes Celeste B. BurnessLesley J. Scott Adis Drug Evaluation 30 September 2015 Pages: 407 - 418